ARS Pharmaceuticals (SPRY) Current Assets (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Current Assets of $245.2 million for Q1 2026, down 13.92% sequentially from $284.9 million in Q4 2025, and down 19.29% YoY from $303.9 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Current Assets (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Current Assets for 7 years, with the latest figure at $245.2 million in Q1 2026.
- Quarterly Current Assets fell 19.29% year-over-year to $245.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.2 million (down 19.29% YoY) and the FY2025 annual result came in at $284.9 million, down 14.78% from the prior year.
- Current Assets declined to $245.2 million in Q1 2026 per SPRY's latest filing, from $284.9 million in the prior quarter.
- Over five years, Current Assets peaked at $338.9 million in Q3 2025 and troughed at $208.8 million in Q3 2024.
- A 5-year average of $265.6 million and a median of $263.1 million in 2022 frame the typical range for Current Assets.
- The widest YoY moves for Current Assets: up 357.27% in 2022, down 30.93% in 2022.
- Over 5 years, Current Assets stood at $277.7 million in 2022, then declined by 16.56% to $231.7 million in 2023, then jumped by 44.26% to $334.3 million in 2024, then decreased by 14.78% to $284.9 million in 2025, then declined by 13.92% to $245.2 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $245.2 million, $284.9 million, and $338.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 211.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.51 Mn |
| Mar 31, 2026 | 245.24 Mn |
| Dec 31, 2025 | 284.90 Mn |
| Sep 30, 2025 | 338.86 Mn |
| Jun 30, 2025 | 281.44 Mn |
| Mar 31, 2025 | 303.86 Mn |
| Dec 31, 2024 | 334.30 Mn |
| Sep 30, 2024 | 208.79 Mn |
| Jun 30, 2024 | 220.74 Mn |
| Mar 31, 2024 | 226.24 Mn |
| Dec 31, 2023 | 231.73 Mn |
| Sep 30, 2023 | 244.47 Mn |
| Jun 30, 2023 | 255.03 Mn |
| Mar 31, 2023 | 267.35 Mn |
| Dec 31, 2022 | 277.70 Mn |
| Sep 30, 2022 | 270.80 Mn |
| Jun 30, 2022 | 263.13 Mn |
| Mar 31, 2022 | 261.33 Mn |
| Dec 31, 2021 | 60.73 Mn |
| Sep 30, 2021 | 305.36 Mn |